Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Apomorphine55
Andrew Lees (neurologue)150
Apomorphine Sauf Andrew Lees (neurologue)" 48
Andrew Lees (neurologue) Sauf Apomorphine" 143
Apomorphine Et Andrew Lees (neurologue) 7
Apomorphine Ou Andrew Lees (neurologue) 198
Corpus5903
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 7.
Ident.Authors (with country if any)Title
000C68 Leon Poltawski [Royaume-Uni] ; Hazel Edwards [Royaume-Uni] ; Amy Todd [Royaume-Uni] ; Tim Watson [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Cherry Ann James [Royaume-Uni]Ultrasound Treatment of Cutaneous Side-Effects of Infused Apomorphine : A Randomized Controlled Pilot Study
001E89 Regina Katzenschlager [Royaume-Uni, Autriche] ; Andrew Hughes [Australie] ; Andrew Evans [Royaume-Uni] ; Alice J. Manson [Royaume-Uni] ; Marion Hoffman [Australie] ; Lesley Swinn [Royaume-Uni] ; Hilary Watt [Royaume-Uni] ; Kailash Bhatia [Royaume-Uni] ; Niall Quinn [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease : A prospective study using single-dose challenges
002006 Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Franck Durif [France]Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study
002858 Alice J. Manson [Royaume-Uni] ; Kirsten Turner [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni]Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients
002E11 M. Merello [Argentine] ; Andrew Lees (neurologue) [Royaume-Uni] ; J. Balej [Argentine] ; A. Cammarota [Argentine] ; R. Leiguarda [Argentine]GPi firing rate modification during beginning-of-dose motor deterioration following acute administration of apomorphine
003677 A. J. Hughes [Royaume-Uni] ; S. Bishop ; B. Kleedorfer ; N. Turjanski ; W. Fernandez ; Andrew Lees (neurologue) [Royaume-Uni] ; G. M. SternSubcateneous apomorphine in Parkinson's disease: response to chronic administration for up to five years
003997 P. A. Kempster ; Andrew Lees (neurologue) [Royaume-Uni] ; P. Crichton ; J. P. Fkankel ; P. ShorvonOff-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024